openPR Logo
Press release

Biotherapeutics Cell Line Development Market: Unmet Medical Needs within Emerging Economies to Drive Growth Prospects

11-23-2017 07:51 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Biotherapeutics Cell Line Development Market: Unmet Medical

The global biotherapeutics cell line development market is highly consolidated and is led by Becton Dickinson and Co. and Beckman Coulter, which are the two leading companies within this market. These two companies collectively accounted for a whopping 85% of the total market in 2015, states Transparency Market Research (TMR) in its latest report. There lies a meager chance for new entrants to enter in the market on account of the high shares held by these two companies. It has also led to a reduced market shares for other companies. Some of the other companies in the global biotherapeutics cell line development market include: Catalent Inc., CMC Biologics, Lonza Group Ltd., Partec, Sony Biotechnology Inc., SAFC, Selexis SA, Boehringer Ingelheim Pharma GmbH & Co KG., ProBioGen AG, and Thermo Fisher Scientific Inc. The possibility of business expansion and growth opportunities lies mostly with the established companies. In the years to come, companies will need to focus on advancements and adoption of latest technology so as to gain a competitive edge above each other.

Read Report Overview @ https://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html

According to TMR, the global market for biotherapeutics cell line development market will be worth US$99.8 mn by 2022. On the basis of geography, North America has been leading in the market from many years. The North American market for biotherapeutics cell line development is predicted to be worth US$41 mn by 2022. Asia Pacific on the other hand is estimated to expand at the fastest pace in the coming years. By process, the single cell cloning segment will continue to enjoy leading status throughout the forecast period. On the basis of cell line development option, the outsourcing segment will emerge victorious for biotherapeutics, stated a TMR analyst.

The growing incidences of chronic diseases and increasing population of aged people are two important factors fueling the growth of the global biotherapeutics cell line development market. The growing geriatric population has led to an increase in the number of cases for degenerative, chronic, and autoimmune diseases. This in turn is favoring the demand for biotherapeutics cell line development. Some of the most prevalent diseases today that are boosting the growth of this market include: cancer, diabetes, and multiple sclerosis. The efficiency offered by biotherapeutics is gaining traction from patients as well as those within the medical line, for use in the treatment of the aforementioned diseases. This in turn is aiding the growth of the market.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

“The stringent policies and regulations regarding the cell culture procedures is anticipated to be a key challenge for the growth of the global biotherapeutics cell line development market,” a TMR analyst said. These policies regulate the production of biotherapeutics and could crush the growth opportunities for several market players. The development of stable cell line producing biologics requires compliance with standard operating procedures. Monitoring of product quality through tests in line with regulations and SOPs is delaying product development and affecting market players. Moreover, such strict regulations act as entry barriers for new players.

On a positive notion however, the unmet medical needs of the patient population in developing economies of Asia Pacific, Latin America, and Africa will ensure a healthy growth of the biotherapeutics cell line development market. The increasing demand for antibodies will also lead to development and progress of the global biotherapeutics cell line development market.

Buy Full Biotherapeutics Cell Line Development Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=8272

About TMR

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biotherapeutics Cell Line Development Market: Unmet Medical Needs within Emerging Economies to Drive Growth Prospects here

News-ID: 829616 • Views: 179

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Biotherapeutics

Biotherapeutics Virus removal filters Market Detailed Analytical Overview by 202 …
The biotherapeutics virus removal filters provide robust and economic solutions to stop the potential viral contaminants in a sample from the desired product. By using virus removal technique, all the non-enveloped viruses can be completely removed from the sample. The biotherapeutics virus removal filters are basically used during the manufacturing of biotherapeutic drug products or samples such as therapeutic replacement enzymes, antibodies, blood, derivatives of plasma and biopharmaceuticals. The biotherapeutics
Global Biotherapeutics Market Overview, Competitive Status Trend and Recent Deve …
MarketResearchReports.Biz adds “Global Biotherapeutics Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Biotherapeutics and the growth estimates for the forecasted period. This report studies the global Biotherapeutics market, analyzes and researches the Biotherapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. Request Sample Copy of the Report @ https://www.marketresearchreports.biz/sample/sample/1677117 This report focuses on the
Biotherapeutics Virus Removal Filters Market Rugged Expansion Foreseen by 2025
Biotherapeutics virus removal filtration is one of the very booming technology adopting by biotechnology and pharmaceutical companies. Virus removability is based on size–exclusion mechanisms: viruses larger than the mean pore size become trapped. The first virus removal filter in biotherapeutics, PlanovaTM, was launched in 1989. It is first filter developed specifically for removing viruses from biotherapeutic products such as biopharmaceuticals and plasma derivatives. These filters are available in pore sizes to
10-11-2017 | Health & Medicine
TMR
Biotherapeutics Cell Line Development Market – Global Industry Analysis 2015
The global biotherapeutics cell line development market is highly consolidated and is led by Becton Dickinson and Co. and Beckman Coulter, which are the two leading companies within this market. These two companies collectively accounted for a whopping 85% of the total market in 2015, states Transparency Market Research (TMR) in its latest report. There lies a meager chance for new entrants to enter in the market on account of
Biotherapeutics Cell Line Development Market: Industry Overview and Key Factors
With the increasing number of recombinant protein therapeutics gaining approval by the U.S. Food and Drug Administration (FDA) annually, there is an increase in the demand of cell lines for production of these biotherapeutics. From 2006 to 2011 an average of 15 novel recombinant protein therapeutics and in 2014, 11 novel recombinant protein therapeutics have been approved by US FDA. About forty-seven monoclonal antibody products have been approved in the
Biotherapeutics Cell Line Development Market: Industry Overview and Key Factors
A high degree of consolidation is the defining feature of the competitive landscape of the global biotherapeutics cell line development market, finds Transparency Market Research. Becton Dickinson and Co. and Beckman Coulter, the top two companies operating in the biotherapeutics cell line development market, accounted for 85% of the overall market in 2015. This consolidation has led to reduced market shares for other players and has also abated the possibility